| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Cepheid, Inc. |
| 1190 Borregas Avenue, Sunnyvale, CA 94089 * (408) 541-4191 |
| Business Description | The company develops, manufactures and markets microfludic systems that integrate, automate and accelerate biological testing. |
| Offering Information Company has | |||
| Trading As | CPHD (NASNTL) | Industry | Manufacturing (SIC 3826) |
| Type of Stock Offered | Common Shares | Filing Date | 4/7/00 |
| Domestic Shares Offered | 5,000,000 | Offer Date | 6/20/00 |
| Foreign Shares Offered | 0 | Filing Range | $10.00 - $12.00 |
| Company Shares | 5,000,000 | Offer Price | $6.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.420 |
| Gross Proceeds | $30,000,000 | Selling | $0.250 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 25,520,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Warburg Dillon Read LLC | Lead Manager | (203) 719-3000 |
| Invemed Associates Inc. | Co-manager | (212) 421-2500 |
| Prudential Vector Healthcare | Co-manager | (800) 546-1231 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 3 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | 3/31/99 | 3/31/00 | ||
| Revenues | - | - | 1.445 | 3.577 | 3.595 | 0.615 | 0.916 |
| Income from Oper. | - | - | -1.358 | -3.591 | -8.061 | -1.956 | -3.412 |
| Net Income | - | - | -1.274 | -3.311 | -7.919 | -1.871 | -3.253 |
| E.P.S | - | - | -7.610 | -1.370 | -1.900 | -0.550 | -4.420 |
| Revenue Growth (%) | - | - | 147.54 | 0.503 | 48.94 | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -7.09 | -1.29 | -2.16 | ||||
| Cash Flow - Inv. | 0.42 | 1.09 | -0.25 | ||||
| Cash Flow - Fin. | 1.08 | -0.02 | 19.34 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 3/31/00 | Financial Ratios | ||||
| Total Assets | 22.09 | Current Assets | 19.66 | Current Ratio | 8.20 |
| Total Liab. | 3.54 | Current Liab. | 2.40 | Debt Ratio | 16.03% |
| Total Equity | 18.55 | Working Cap. | 17.26 | Debt to Equity Ratio | 0.19 |
| Cash | 18.42 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to fund research and development activities, expand manufacturing and customer service for existing products, continue development and manufacturing of additional products, for other working capital and for general corporate purposes for capital expenditures, including expansion of facilities and to support possible acquisitions. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Heller, Ehrman, White & McAuliffe |
| Bank's Law Firm | Dewey Ballantine |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Wheatley Partners II, LP | 10.80 | |
| Invemed Associates LLC | 8.60 | |
| Note: represents ownership of 5% or more prior to the offering. | ||